全文获取类型
收费全文 | 167篇 |
免费 | 13篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 1篇 |
基础医学 | 21篇 |
口腔科学 | 10篇 |
临床医学 | 7篇 |
内科学 | 83篇 |
特种医学 | 5篇 |
外科学 | 9篇 |
药学 | 2篇 |
肿瘤学 | 37篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 4篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 5篇 |
2015年 | 5篇 |
2014年 | 8篇 |
2013年 | 5篇 |
2012年 | 11篇 |
2011年 | 5篇 |
2010年 | 6篇 |
2009年 | 3篇 |
2008年 | 4篇 |
2007年 | 5篇 |
2006年 | 4篇 |
2005年 | 7篇 |
2004年 | 9篇 |
2003年 | 10篇 |
2002年 | 6篇 |
2001年 | 4篇 |
2000年 | 14篇 |
1999年 | 7篇 |
1998年 | 7篇 |
1997年 | 7篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 4篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1983年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有180条查询结果,搜索用时 140 毫秒
1.
Takeshita M Yamamoto M Kikuchi M Kimura N Nakayama J Uike N Daimaru H Sawada H Okamura T 《American journal of clinical pathology》2000,113(2):201-211
We compared the expression of cell adhesion molecules (CAMs), cytotoxic granule proteins, and apoptosis-related proteins by immunohistology and in situ terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP nick end labeling (TUNEL) of 10 cases of cutaneous CD56+ NK/T cell lymphoma with and 6 cases without angiodestruction. Lymphoma cells in cases with angiodestruction frequently expressed CAMs CD2, CD11a, and CD49d and their ligands CD58, CD54, and CD106 and were positive for CD122 and cytotoxic granule proteins TIA1, perforin, and granzyme B. Lymphoma cells in cases without angiodestruction mostly were negative for CD2, CD58, CD54, CD106, and TIA1 and weakly positive for perforin and granzyme B. In the TUNEL method, mean apoptotic indices (AI) for cases with angiodestruction showed a higher percentage than those without angiodestruction. CD95L, CD95, apoptosis-induced cysteine protease CPP32, apoptosis-promoting protein Bax, and proliferating marker (MIB1) frequently were positive in the lymphoma cells of cases with angiodestruction, but there was no expression of apoptosis-inhibitor protein Bcl2. In most cases without angiodestruction, lymphoma cells were positive for CD95L and Bax and negative for CD95, CPP32, and MIB1. CAMs and the 3 cytotoxic granule proteins and an apoptosis pathway might be important factors in the paracrine and autocrine mechanisms of tissue necrosis in cutaneous CD56+ NK/T cell lymphoma. 相似文献
2.
Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. 总被引:5,自引:0,他引:5
T Fukushima Y Miyazaki S Honda F Kawano Y Moriuchi M Masuda R Tanosaki A Utsunomiya N Uike S Yoshida J Okamura M Tomonaga 《Leukemia》2005,19(5):829-834
Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy. Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL. To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002. All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients. The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3%, respectively. Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect. However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse. These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD. A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted. 相似文献
3.
Analyses of Genetic and Clinical Parameters for Screening Patients With Inherited Thrombocytopenia with Small or Normal‐Sized Platelets
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Meri Ouchi‐Uchiyama MD PhD Yoji Sasahara MD PhD Atsuo Kikuchi MD PhD Kumiko Goi MD PhD Takaya Nakane MD PhD Mitsuru Ikeno MD PhD Yasushi Noguchi MD PhD Naokuni Uike MD PhD Yuji Miyajima MD PhD Kousaku Matsubara MD PhD Katsuyoshi Koh MD PhD Kanji Sugita MD PhD Masue Imaizumi MD PhD Shigeo Kure MD PhD 《Pediatric blood & cancer》2015,62(12):2082-2088
4.
Nobuyasu Hirai Kei Kasahara Hiroyuki Fujikura Shingo Yoshihara Taku Ogawa Yoshihiko Ogawa Naokuni Hishiya Yuki Suzuki Ryuichi Nakano Hisakazu Yano Masahide Yoshikawa Keiichi Mikasa 《Journal of infection and chemotherapy》2018,24(7):570-572
Mycotic aneurysm is a rare but life-threatening disease that warrants an integrated therapeutic approach involving surgical intervention and prolonged antibiotic use. However, the causative organisms are often unidentified because antibiotics started empirically render blood and tissue cultures negative. Molecular diagnosis has been reported to be useful in such culture-negative cases. We report a case of a culture-negative mycotic aortic aneurysm due to Haemophilus influenzae, diagnosed by direct 16S rRNA polymerase chain reaction (PCR) and sequencing of the resected aneurysm tissue. PCR for serotype revealed type b, and PCR and sequencing of the ftsI gene revealed alterations in penicillin-binding protein 3, suggesting resistance to ampicillin. Multilocus sequence typing demonstrated that the isolate belonged to sequence type 54. 相似文献
5.
Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Youko Suehiro Atsuhiko Hasegawa Tadafumi Iino Amane Sasada Nobukazu Watanabe Masao Matsuoka Ayako Takamori Ryuji Tanosaki Atae Utsunomiya Ilseung Choi Tetsuya Fukuda Osamu Miura Shigeo Takaishi Takanori Teshima Koichi Akashi Mari Kannagi Naokuni Uike Jun Okamura 《British journal of haematology》2015,169(3):356-367
Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type‐I (HTLV‐I)‐infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV‐I Tax‐specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti‐ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate‐ to high‐risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax‐specific CTL responses were observed with peaks at 16–20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide‐pulsed DC vaccine is a safe and promising immunotherapy for ATL. 相似文献
6.
Inami N Sato H Makiyama K Song K Murayama I Takayama T 《Hepato-gastroenterology》2004,51(60):1717-1721
BACKGROUND/AIMS: Quality of life can be adversely affected in many patients who suffer phonation disorders such as hoarseness and dysphonia following esophagectomy. The present study investigated postoperative phonation disorders in 15 patients who underwent esophagectomy for esophageal cancer. METHODOLOGY: None of the patients had signs of hoarseness before or after surgery. Aerodynamic testing to assess phonatory function testing and laryngoscopy for observing laryngeal movements were performed before and after surgery. As a control, the same tests were conducted in 20 patients treated for gastric cancer by gastrectomy. RESULTS: For esophagectomy patients, mean postoperative flow rate was significantly increased and maximum postoperative phonation time was significantly decreased after operation. Laryngoscopy confirmed postoperative paralysis of left laryngeal movements and excessive adduction of the right, unaffected vocal cord during phonation in 8 of 15 esophagectomy patients, although hoarseness was not reported by any patient. No significant changes were observed for mean postoperative flow rate or maximum postoperative phonation time following surgery in gastrectomy patients. CONCLUSIONS: Surgical procedures in the vicinity of the recurrent laryngeal nerve appear to be the cause of postoperative phonation disorders in patients undergoing esophagectomy for esophageal cancer, and these disorders can occur in the absence of symptoms such as hoarseness and dysphonia. 相似文献
7.
The leucine twenty homeobox (LEUTX) gene,which lacks a histone acetyltransferase domain,is fused to KAT6A in therapy‐related acute myeloid leukemia with t(8;19)(p11;q13)
下载免费PDF全文
![点击此处可从《Genes, chromosomes & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
8.
9.
K Itoh T Ohtsu H Fukuda Y Sasaki M Ogura Y Morishima T Chou K Aikawa N Uike F Mizorogi T Ohno S Ikeda T Sai M Taniwaki F Kawano M Niimi T Hotta M Shimoyama K Tobinai 《Annals of oncology》2002,13(9):1347-1355
BACKGROUND: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is accepted as the best available standard treatment for first-line chemotherapy in aggressive non-Hodgkin's lymphoma (NHL). However, the therapeutic efficacy of CHOP remains unsatisfactory, particularly in high-intermediate risk and high risk patients, and a new strategy is warranted in this patient population. The aim of the present study was to explore a suitable therapeutic-intensified regimen for the treatment of aggressive NHL. PATIENTS AND METHODS: Between May 1995 and July 1998, a total of 70 patients with high-intermediate risk or high risk aggressive NHL, according to the International Prognostic Index, were enrolled and randomly assigned to receive either eight cycles of standard CHOP (cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) and prednisolone 100 mg for 5 days) every 2 weeks, or six cycles of dose-escalated CHOP (cyclophosphamide 1500 mg/m(2), doxorubicin 70 mg/m(2), vincristine 1.4 mg/m(2) and prednisolone 100 mg for 5 days) every 3 weeks. Lenograstim (glycosylated rHuG-CSF), at a dose of 2 micro g/kg/day s.c., was administered daily from day 3 until day 13 with biweekly CHOP and until day 20 with the dose-escalated CHOP. The primary endpoint was complete response rate. RESULTS: The complete response rate was 60% [21 of 35; 95% confidence interval (CI) 42% to 76%] with biweekly CHOP and 51% (18 of 35; 95% CI 34% to 69%) with dose-escalated CHOP. The major toxicity was grade 4 neutropenia and was more frequent in the dose-escalated CHOP arm (86%) than in the biweekly CHOP arm (50%). Grade 4 thrombocytopenia was also more frequent in the dose-escalated CHOP arm (20%) than the biweekly CHOP arm (3%). Non-hematological toxicities were acceptable in both arms. One treatment-related death (due to cardiac arrhythmia) was observed in a dose-escalated CHOP patient. Progression-free survival at 3 years was 43% (95% CI 27% to 59%) in the biweekly CHOP arm and 31% (95% CI 16% to 47%) in the dose-escalated CHOP arm. Although seven patients were deemed ineligible by central review of the pathological diagnosis, the results for both eligible and all enrolled patients were similar. CONCLUSIONS: Similar complete response rates and progression-free survival rates, but lower toxicity, indicated that biweekly CHOP was superior to dose-escalated CHOP in the treatment of aggressive NHL. Based on these results, the Lymphoma Study Group of the Japan Clinical Oncology Group is conducting a randomized phase III study comparing biweekly CHOP with standard CHOP in newly diagnosed patients with advanced-stage aggressive NHL. 相似文献
10.
Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group 总被引:1,自引:0,他引:1
Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y 《Japanese journal of clinical oncology》1997,27(3):146-153
Cladribine (2-chlorodeoxyadenosine;) is a purine analogue with clinical
activity against hairy cell leukemia, chronic lymphocytic leukemia and
indolent lymphoma. To clarify the toxicity profiles of cladribine, we
conducted a phase I and pharmacological study of cladribine with a schedule
of seven-day continuous intravenous infusion every 28 days up to a maximum
of three cycles. We enrolled 10 previously-treated patients with various
lymphoid malignancies. No dose-limiting toxicity (grade 4 hematologic
and/or grade 3 or more non-hematologic) was observed in the three patients
who received 0.06 mg/kg/day (Level 1). Of the seven patients who received
0.09 mg/kg/day (Level 2), one patient developed grade 4 hypoxemia and grade
4 thrombocytopenia, and another developed grade 4 neutropenia. Of the seven
patients treated at Level 2, one with cutaneous T-cell lymphoma attained
complete remission, and one with mantle cell lymphoma, one with chronic
lymphocytic leukemia and one with adult T-cell leukemia-lymphoma attained
partial remission. A pharmacokinetic analysis of the seven patients without
leukemic cells showed that their area under the concentration versus time
curves of plasma cladribine increased dose-dependently from 2661.3 +/-
300.4 nM x h at Level 1 (n = 3) to 3411.3 +/- 341.0 nM x h at Level 2 (n =
4) (P = 0.034). We conclude that the recommended phase II dose of
cladribine (0.09 mg/kg/day as a seven-day continuous i.v. infusion) in
Caucasian patients can be safely administered to Japanese patients. The
encouraging results prompted us to plan subsequent phase II studies of
cladribine against adult T-cell leukemia-lymphoma, hairy cell leukemia and
indolent lymphoma.
相似文献